Angiogenesis as a target in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 62, Issue SUPPL. 2, 2003, Pages 60-67

  Koch, A E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; ANGIOPOIETIN; ANGIOSTATIN; CELL ADHESION MOLECULE; CHEMOKINE; CYCLOSPORIN; CYTOKINE; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; FUMAGILLOL CHLOROACETYLCARBAMATE; GLYCOCONJUGATE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 18; PACLITAXEL; SALAZOSULFAPYRIDINE; THALIDOMIDE; THROMBOSPONDIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADJUVANT ARTHRITIS; ANGIOGENESIS; BLOOD VESSEL PERMEABILITY; CONFERENCE PAPER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCID MOUSE; SEPARATION TECHNIQUE; TARGET CELL;

EID: 0142187335     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.62.suppl_2.ii60     Document Type: Conference Paper

References (134)

1. Walsh DA, Pearson CI. Angiogenesis in the pathogenesis of inflammatory joint and lung diseases. Arthritis Res 2001;3:147-53.
2. Walsh DA. Angiogenesis and arthritis. Rheumatology (Oxford) 1999;38:103-12.
3. Walsh DA, Haywood L. Angiogenesis:a therapeutic target in arthritis. Curr Opin Investig Drugs 2001;2:1054-63.
4. Brenchley PE. Antagonising angiogenesis in rheumatoid arthritis. Ann Rheum Dis 2001;60(suppl III):iii71-4.
5. Brenchley PEC. Angiogenesis in inflammatory joint disease: a target for therapeutic intervention. Clin Exp Immunol 2000;121:426-9.
6. Koch AE. The role of angiogenesis in rheumatoid arthritis: recent developments. Ann Rheum Dis 2000;59(suppl I):165-71.
7. Koch AE. Angiogenesis:implications for rheumatoid arthritis. Arthritis Rheum 1998;41:951-62.
8. Szekanecz Z, Koch AE. Chemokines and angiogenesis. Curr Opin Rheumatol 2001;13:202-8.
9. Szekanecz Z, Szegedi G, Koch AE. Angiogenesis in rheumatoid arthritis: pathogenic and clinical significance. J Invest Med 1998;46:27-41.
10. Szekanecz Z, Halloran MM, Haskell CA, Shah MR, Polverini PJ, Koch AE. Mediators of angiogenesis: the role of cellular adhesion molecules. Trends in Glycoscience and Glycotechnology 1999;11:73-93.
11. Walsh DA, Mapp PI, Wharton J, Rutherford RAD, Kidd BL, Revell PA, et al. Localization and characterization of substance P binding to human synovial tissue in rheumatoid arthritis. Ann Rheum Dis 1992;51:313-17.
12. Brenchley PE. Angiogenesis in inflammatory joint disease: a target for therapeutic intervention. Clin Exp Immunol 2000;121:426-9.
13. Paleolog EM, Moitla JM. Angiogenesis in arthritis: role in disease pathogenesis and as a potential therapeutic target. Angiogen 1998;2:295-307.
14. Paleolog EM, Fava RA. Angiogenesis in rheumatoid arthritis: implications for future therapeutic strategies. Springer Semin Immunopathol 1998;20:73-94.
15. Paleolog EM. Angiogenesis: a critical process in the pathogenesis of RA - a role for VEGF? Br J Rheumatol 1996;35:917-19.
16. Folkman J, Klagsbrun M, Sasse J, Wadzinski M, Ingber D, Vlodavsky I. A heparin-binding angiogenic protein - basic fibroblast growth factor - is stored within basement membrane. Am J Pathol 1988;130:393-400.
17. Yamashita A, Yonemitsu Y, Okano S, Nakagawa K, Nakashima Y, Irisa T, et al. Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats. J Immunol 2002;168:450-7.
18. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
19. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Molec Med 1999;77:527-43.
20. Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995;36:127-37.
21. Koch AE, Harlow LA, Haines GK, Amento EP, Unemori EN, Wong WL, et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994;152:4149-56.
22. Jackson JR, Minton JA, Ho ML, Wei N, Winkler JD. Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1beta. J Rheumatol 1997;24:1253-9.
23. Harada M, Mitsuyama K, Yoshida H, Sakisaka S, Taniguchi E, Kawaguchi T, et al. Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand J Rheumatol 1998;27:377-80.
24. Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B, et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994;180:341-6.
25. Kikuchi K, Kubo M, Kadono T, Yazawa N, Ihn H, Tamaki K. Serum concentrations of vascular endothelial growth factor in collagen diseases. Br J Dermatol 1998;139:1049-51.
26. Bottomley MJ, Webb NJ, Watson CJ, Holt PJ, Freemont AJ, Brenchley PE. Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor (VEGF): specific up-regulation by tumour necrosis factor-alpha (TNF-alpha) in synovial fluid. Clin Exp Immunol 1999;117:171-6.
27. Ben-Av P, Crofford LJ, Wilder RL, Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett 1995;372:83-7.
28. Nagashima M, Yoshino S, Ishiwata T, Asano G. Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. J Rheumatol 1995;22:1624-30.
29. Berse B, Hunt JA, Diegel RJ, Morganelli P, Yeo K, Brown F, et al. Hypoxia augments cytokine (transforming growth factor-beta (TGF-beta) and IL-1-induced vascular endothelial growth factor secretion by human synovial fibroblasts. Clin Exp Immunol 1999;115:176-82.
30. Cho CS, Cho ML, Min SY, Kim WU, Min DJ, Lee SS, et al. CD40 engagement on synovial fibroblast up-regulates production of vascular endothelial growth factor. J Immunol 2000;164:5055-61.
31. Mason JC, Lidington EA, Yarwood H, Lublin DM, Haskard DO. induction of endothelial cell decay-accelerating factor by vascular endothelial growth factor: a mechanism for cytoprotection against complement-mediated injury during inflammatory angiogenesis. Arthritis Rheum 2001;44:138-50.
32. Paavonen K, Mandelin J, Partanen T, Jussila L, Li TF, Ristimaki A, et al. Vascular endothelial growth factors C and D and their VEGFR-2 and 3 receptors in blood and lymphatic vessels in healthy and arthritic synovium. J Rheumatol 2002;29:39-45.
33. Cho ML, Cho CS, Min SY, Kim SH, Lee SS, Kim WU, et al. Cyclosporine inhibition of vascular endothelial growth factor production in rheumatoid synovial fibroblasts. Arthritis Rheum 2002;46:1202-9.
34. Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 1998;41:1258-65.
35. Sekimoto T, Hamada K, Oike Y, Matsuoka T, Matsumoto M, Chosa E, et al. Effect of direct angiogenesis inhibition in rheumatoid arthritis using a soluble vascular endothelial growth factor receptor 1 chimeric protein. J Rheumatol 2002;29:240-5.
36. Nagashima M, Tanaka H, Takahashi H, Tachihara A, Tanaka K, Ishiwata T, et al. Study of the mechanism involved in angiogenesis and synovial cell proliferation in human synovial tissues of patients with rheumatoid arthritis using SCID mice. Lab Invest 2002;82:981-8.
37. Lu J, Kasama T, Kobayashi K, Yoda Y, Shiozawa F, Hanyuda M, et al. Vascular endothelial growth factor expression and regulation of murine collagen-induced arthritis. J Immunol 2000;164:5922-7.
38. Sone H, Kawakami Y, Sakauchi M, Nakamura Y, Takahashi A, Shimano H, et al. Neutralization of vascular endothelial growth factor prevents collagen-induced arthritis and ameliorates established disease in mice. Biochem Biophys Res Commun 2001;281:562-8.
39. de Bandt M, Grossin M, Weber AJ, Chopin M, Elbim C, Pla M, et al. Suppression of arthritis and protection from bone destruction by treatment with TNP-470/AGM-1470 in a transgenic mouse model of rheumatoid arthritis. Arthritis Rheum 2000;43:2056-63.
40. Miotla J, Maciewicz R, Kendrew J, Feldmann M, Paleolog E. Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab Invest 2000;80:1195-205.
41. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, et al. Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002;8:831-40.
42. Jones A, Harris AL. New developments in angiogenesis: a major mechanism for tumor growth and target for therapy. Cancer J Sci Am 1998;4:209-17.
43. Hollander AP, Corke KP, Freemont AJ, Lewis CE. Expression of hypoxia-inducible factor 1alpha by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint. Arthritis Rheum 2001;44:1540-4.
44. Cramer T, Yamanishi Y, Clausen BE, Forster I, Pawlinski R, Mackman N, et al. HIF-1 alpha is essential for myeloid cell-mediated inflammation. Cell 2003;112:645-57.
45. Park CC, Morel JC, Amin MA, Connors MA, Harlow LA, Koch AE. Evidence of IL-18 as a novel angiogenic mediator. J Immunol 2001;167:1644-53.
46. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992;258:1798-801.
47. Stricter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995;270:27348-57.
48. Salcedo R, Wasserman K, Young HA, Grimm MC, Howard OM, Anver MR, et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: in vivo neovascularization induced by stromal-derived factor-1 alpha. Am J Pathol 1999;154:1125-35.
49. Hitchon C, Wong K, Ma G, Reed J, Lyttle D, El-Gabalawy H. Hypoxia-induced production of stromal cell-derived factor 1 (CXCL12) and vascular endothelial growth factor by synovial fibroblasts. Arthritis Rheum 2002;46:2587-97.
50. Nanki T, Hayashida K, El-Gabalawy HS, Suson S, Shi K, Girschick HJ, et al. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4(+) T cell accumulation in rheumatoid arthritis synovium. J Immunol 2000;165:6590-8.
51. Blades MC, Ingegnoli F, Wheller SK, Manzo A, Wahid S, Panayi GS, et al. Stromal cell-derived factor 1 (CXCL12) induces monocyte migration into human synovium transplanted onto SCID mice. Arthritis Rheum 2002;46:824-36.
52. Volin MV, Woods JM, Amin MA, Connors MA, Harlow LA, Koch AE. Fractalkine: a novel angiogenic chemokine in rheumatoid arthritis. Am J Pathol 2001;159:1521-30.
53. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997;385:640-4.
54. Johnson BA, Haines GK, Harlow LA, Koch AE. Adhesion molecule expression in human synovial tissue. Arthritis Rheum 1993;36:1 37-46.
55. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994;264:569-71.
56. Pirila L, Heino J. Altered integrin expression in rheumatoid synovial lining type B cells:in vitro cytokine regulation of alpha 1 beta 1, alpha 6 beta 1, and alpha v beta 5 integrins. J Rheumatol 1996;23:1691-8.
57. Storgard CM, Stupack DG, Jonczyk A, Goodman SL, Fox RI, Cheresh DA. Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J Clin Invest 1999;103:47-54.
58. Badger AM, Blake S, Kapadia R, Sarkar S, Levin J, Swift BA, et al. Disease-modifying activity of SB 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis. Arthritis Rheum 2001;44:128-37.
59. Gerlag DM, Borges E, Tak PP, Ellerby HM, Bredesen DE, Pasqualini R, et al. Suppression of murine collagen-induced arthritis by targeted apoptosis of synovial neovasculature. Arthritis Res 2001;3:357-61.
60. Neidhart M, Wehrli R, Bruhlmann P, Michel BA, Gay RE, Gay S. Synovial fluid CD146 (MUC18), a marker for synovial membrane angiogenesis in rheumatoid arthritis. Arthritis Rheum 1999;42:622-30.
61. Ferrara N. Missing link in angiogenesis. Nature 1995;376:467.
62. Koch AE, Halloran MM, Haskell CJ, Shah MR, Polverini PJ. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 1995;376:517-19.
63. 62a Kumar P, Amin MA, Harlow LA, Polverini PJ, Koch AE. Src and phosphatidylinositol 3-kinase mediate soluble E-selectin-induced angiogenesis. Blood 2003;101:3960-8.
64. Paleolog EM, Hunt M, Elliott MJ, Feldmann M, Maini RN, Woody JN. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum 1996;39:1082-91.
65. Halloran MM, Carley WW, Polverini PJ, Haskell CJ, Phan S, Anderson BJ, et al. Ley/H: an endothelial-selective, cytokine-inducible, angiogenic mediator. J Immunol 2000;164:4868-77.
66. Holgersson J, Breimer ME, Samuelsson BE. Basic biochemistry of cell surface carbohydrates and aspects of the tissue distribution of histo-blood group ABH and related glycosphingolipids. Apmis Suppl 1992;27:18-27.
67. Appelmelk BJ, Simoons-Smit I, Negrini R, Moran AP, Aspinall GO, Forte JG, et al. Potential role of molecular mimicry between Helicobacter pylori lipopolysaccharide and host Lewis blood group antigens in autoimmunity. Infect Immun 1996;64:2031-40.
68. Aspinall GO, Monteiro MA. Lipopolysaccharides of Helicobacter pylori strains P466 and MO19: structures of the O antigen and core oligosaccharide regions. Biochemistry 1996;35:2498-504.
69. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
70. Hohenester E, Sasaki T, Olsen BR, Timpl R. Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution. Embo J 1998;17:1656-64.
71. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996;87:1161-9.
72. Folkman J, D'Amore PA. Blood vessel formation: what is its molecular basis? Cell 1996;87:1153-5.
73. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996;87:1171-80.
74. Shahrara S, Volin MV, Connors MA, Haines GK, Koch AE. Differential expression of the angiogenic Tie receptor family in arthritic and normal synovial tissue. Arthritis Res 2002;4:201-8.
75. Gravallese EM, Pettit AR, Lee R, Madore R, Manning C, Tsay A, et al. Angiopoietin-1 is expressed in the synovium of patients with rheumatoid arthritis and is induced by tumour necrosis factor alpha. Ann Rheum Dis 2003;62:100-7.
76. Vikkula M, Boon LM, Carraway KL, Calvert JT, Diamonti AJ, Goumnerov B, et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor kinase TIE2. Cell 1996;87:1153-5.
77. Uchida T, Nakashima M, Hirota Y, Miyazaki Y, Tsukazaki T, Shindo H. Immunohistochemical localisation of protein tyrosine kinase receptors Tie-1 and Tie-2 in synovial tissue of rheumatoid arthritis:correlation with angiogenesis and synovial proliferation. Ann Rheum Dis 2000;59:607-14.
78. Homandberg GA, Williams JE, Grant D, Schumacher B, Eisenstein R. Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth. Am J Pathol 1985;120:327-32.
79. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al. Angiostatin:a novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma. Cell 1994;79:315-28.
80. Clapp C, Martial JA, Guzman RC, Rentier-Delure F, Weiner RI. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 1993;133:1292-9.
81. Ferrara N, Clapp C, Weiner R. The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. Endocrinology 1991;129:896-900.
82. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990;87:6624-8.
83. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000;6:41-8.
84. Vazquez F, Hastings G, Ortega MA, Lane TF, Oikemus S, Lombardo M, et al. METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. J Biol Chem 1999;274:23349-57.
85. Koch AE, Szekanecz Z, Friedman J, Haines GK, Longman CB, Bouck NP. Effects of thrombospondin-1 on disease course and angiogenesis in rat adjuvant-induced arthritis. Clin Immunol Immunopathol 1998;86:199-208.
86. Gately S, Twardowski P, Stack MS, Patrick M, Boggio L, Cundiff DL, et al. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res 1996;56:4887-90.
87. Cao Y, Ji RW, Davidson D, Schaller J, Marti D, Sohndel S, et al. Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells. J Biol Chem 1996;271:29461-7.
88. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996;2:689-92.
89. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149-53.
90. Moser TL, Stack MS, Asplin I, Enghild JJ, Hojrup P, Everitt L, et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci USA 1999;96:2811-16.
91. Claesson-Welsh L, Welsh M, Ito N, Anand-Apte B, Soker S, Zetter B, et al. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci USA 1998;95:5579-83.
92. Kim JM, Ho SH, Pork EJ, Hahn W, Cho H, Jeong JG, et al. Angiostatin gene transfer as an effective treatment strategy in murine collagen-induced arthritis. Arthritis Rheum 2002;46:793-801.
93. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
94. Nagashima M, Asano G, Yoshino S. Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis. J Rheumatol 2000;27:2339-42.
95. Yin G, Liu W, An P, Li P, Ding I, Planelles V, et al. Endostatin gene transfer inhibits joint ongiogenesis and pannus formation in inflammatory arthritis. Mol Ther 2002;5:547-54.
96. Moses MA, Sudhalter J, Langer R. Identification of an inhibitor of neovascularization from cartilage. Science 1990;248:1408-10.
97. Moses MA. A cartilage-derived inhibitor of neovascularization and metalloproteinases. Clin Exp Rheumatol 1993;11(suppl 8):S67-9.
98. Kuettner KE, Pauli BU. Inhibition of neovascularization by a cartilage factor. Ciba Found Symp 1983;100:163-73.
99. Brem H, Folkman J. Inhibition of tumor angiogenesis mediated by cartilage. J Exp Med 1975;141:427-39.
100. Langer R, Brem H, Falterman K, Klein M, Folkman J. Isolation of a cartilage factor that inhibits tumor neovascularization. Science 1976;193:70-2.
101. Lee A, Langer R. Shark cartilage contains inhibitors of tumor angiogenesis. Science 1983;221:1185-7.
102. Moses MA, Wiederschain D, Wu I, Fernandez CA, Ghazizdeh V, Lane WS, et al. Troponin I is present in human cartilage and inhibits angiogenesis. Proc Natl Acad Sci USA 1999;96:2645-50.
103. Moissec P, Briolay J, Dechanet J, Wijdenes J, Martinez-Valdez H, Banchereau J. Inhibition of the production of proinflammatory cytokines and immunoglobulins by interleukin-4 in an ex vivo model of rheumatoid synovitis. Arthritis Rheum 1992;35:874-83.
104. Woods JM, Katschke KJ Jr, Volin MV, Ruth JH, Woodruff DC, Amin MA, et al. IL-4 adenoviral gene therapy reduces inflammation, proinflammatory cytokines, vascularization, and bony destruction in rat adjuvant-induced arthritis. J Immunol 2001;166:1214-22.
105. Woods JM, Tokuhira M, Berry JC, Katshke KJ Jr, Kurata H, Damergis JA Jr, et al. Interleukin-4 adenoviral gene therapy reduces production of inflammatory cytokines and prostaglandin E2 by rheumatoid arthritis synovium ex vivo. J Investig Med 1999;47:285-92.
106. Volpert OV, Fong T, Koch AE, Peterson JD, Waltenbaugh C, Tepper RI, et al. Inhibition of angiogenesis by interleukin 4. J Exp Med 1998;188:1039-46.
107. Coxon A, Bolon B, Estrada J, Kaufman S, Scully S, Rattan A, et al. Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis. Arthritis Rheum 2002;46:2604-12.
108. Oliver SJ, Cheng TP, Banquerigo ML, Brahn E. Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin:reduction of vascular endothelial growth factor (VEGF). Cell Immunol 1995;166:196-206.
109. Hauschild A, Kroeger H, Mitchison NA, Ugrinovic S, Zwingenberger K. Thalidomide therapy of established collagen-induced arthritis (CIA) not accompanied by an evident Th2 shift. Clin Exp Immunol 1997;108:428-31.
110. Gutierrez-Rodriguez O, Starusta-Bacal P, Gutierrez-Montes O. Treatment of refractory rheumatoid arthritis - the thalidomide experience. J Rheumatol 1989;16:158-63.
111. Huizinga TW, Dijkmans BA, van der Velde EA, van de Pouw Kraan TC, Verweij CL, Breedveld FC. An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis. Ann Rheum Dis 1996;55:833-6.
112. Kusaka M, Sudo K, Fujita T, Marui S, Itoh F, Ingber D, et al. Potent anti-angiogenic action of AGM-1470:comparison to the fumagillin parent. Biochem Biophys Res Commun 1991;174:1070-6.
113. Antoine N, Greimers R, De Roanne C, Kusaka M, Heinen E, Simar LJ, et al. AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle. Cancer Res 1994;54:2073-6.
114. Kusaka M, Sudo K, Matsutani E, Kozai Y, Marui S, Fujita T, et al. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer 1994;69:212-16.
115. Peacock DJ, Banquerigo ML, Brahn E. Angiogenesis inhibition suppresses collagen arthritis. J Exp Med 1992;175:1135-8.
116. Peacock DJ, Banquerigo ML, Brahn E. A novel angiogenesis inhibitor suppresses rat adjuvant arthritis. Cell Immunol 1995;160:178-84.
117. Mori S, Yoshikawa H, Hashimoto J, Ueda T, Funai H, Kato M, et al. Antiangiogenic agent (TNP-470) inhibition of ectopic bone formation induced by bone morphogenetic protein-2. Bone 1998;22:99-105.
118. Madhok R, Wijelath E, Smith J, Watson J, Sturrock RD, Capell HA. Is the beneficial effect of sulfasalazine due to inhibition of synovial neovascularization? J Rheumatol 1991;18:199-202.
119. Volin MV, Harlow LA, Woods JM, Campbell PL, Amin MA, Tokuhira M, et al. Treatment with sulfasalazine or sulfapyridine, but not 5-aminosalicyclic acid, inhibits basic fibroblast growth factor-induced endothelial cell chemotaxis. Arthritis Rheum 1999;42:1927-35.
120. Arsenault AL, Lhotak S, Hunter WL, Banquerigo ML, Brahn E. Taxol involution of collagen-induced arthritis: ultrastructural correlation with the inhibition of synovitis and neovascularization. Clin Immunol Immunopathol 1998;86:280-9.
121. Josefsson E, Tarkowski A. Suppression of type II collagen-induced arthritis by the endogenous estrogen metabolite 2-methoxyestradiol. Arthritis Rheum 1997;40:154-63.
122. Ziche M, Jones J, Gullino PM. Role of prostaglandin E1 and copper in angiogenesis. J Natl Cancer Inst 1982;69:475-82.
123. Hla T, Ristimaki A, Appleby S, Barriocanal JG. Cyclooxygenase gene expression in inflammation and angiogenesis. Ann N Y Acad Sci 1993;696:197-204.
124. Majima M, Isono M, Ikeda Y, Hayashi I, Hatanaka K, Harada Y, et al. Significant roles of inducible cyclooxygenase (COX)-2 in angiogenesis in rat sponge implants. Jpn J Pharmacol 1997;75:105-14.
125. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16.
126. Daniel TO, Liu H, Morrow JD, Crews BC, Marnett LJ. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 1999;59:4574-7.
127. Fraser A, Fearon U, Reece R, Emery P, Veale DJ. Matrix metalloproteinase 9, apoptosis, and vascular morphology in early arthritis. Arthritis Rheum 2001;44:2024-8.
128. Ballara S, Taylor PC, Reusch P, Marme D, Feldmann M, Maini RN, et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 2001;44:2055-64.
129. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000;95:952-8.
130. Gehling UM, Ergun S, Schumacher U, Wagener C, Pantel K, Otte M, et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 2000;95:3106-12.
131. Eichmann A, Corbel C, Nataf V, Vaigot P, Breant C, Le Douarin NM. Ligand-dependent development of the endothelial and hemopoietic lineages from embryonic mesodermal cells expressing vascular endothelial growth factor receptor 2. Proc Natl Acad Sci USA 1997;94:5141-6.
132. Freedman SB, Isner JM. Therapeutic angiogenesis for ischemic cardiovascular disease. J Mol Cell Cardiol 2001;33:379-93.
133. Shyu KG, Manor O, Magner M, Yancopoulos GD, Isner JM. Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. Circulation 1998;98:2081-7.
134. Isner JM, Baumgartner I, Rauh G, Schainfeld R, Blair R, Manor O, et al. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor:preliminary clinical results. J Vasc Surg 1998;28:964-73; discussion 73-5.